AVITA Therapeutics Inc (ASX:AVH) revealed preliminary Q4 and FY20 results, together with a company update.
- In the fourth quarter, total global net revenue for the fourth quarter stood at US$3.88 million and total consolidated sales for FY20 (year ended 30 June 2020) were reported to be US$14.32 million.
- S. RECELL® System sales in Q4 and FY20 reported to be US$3.79 million and US$13.79 million, respectively.
- At the end of the fourth quarter, AVITA had cash and cash equivalents of nearly US$73.84 million.
AVH quoted at A$8.140 down by 4.46% at AEST 12:31 PM.